(TEM) Tempus AI, Inc. Business Model Canvas Research

Biotechnology company clients use Tempus AI for data access, analytics, cloud compute, and research tools, so the relationship goes beyond diagnostics and supports drug discovery and trial design. This broader model helped Tempus AI scale its 2024 revenue to $531.8 million, showing how biotech demand can deepen platform use.

• Data access for R&D
• Cloud-based analytics tools
• Supports non-diagnostic growth

Physicians, lab partners, and other clinical entities are Tempus AI, Inc.'s core demand engine: their orders feed specimen volume and keep the diagnostics workflow moving. Tempus AI reported $693.4 million in revenue for 2024, and this partner-led model is what turns clinical referrals into recurring test demand.

• Referrals drive testing volume
• Labs enable specimen workflows
• Clinicians support repeat demand

Tempus AI, Inc.’s Trials program matches patients to clinical trials, using its data and analytics to help pharma recruit faster. In Q1 2025, Tempus AI reported revenue of $255.7 million, showing the scale behind this diagnostics-to-research link.

• Matches patients to trials
• Supports pharma recruitment
• Connects testing and research

Tempus AI’s key work is AI and cloud analytics development: it builds cloud computing services, algorithm-driven tests, and software platforms that feed both diagnostics and enterprise research. In 2024, Tempus said revenue reached about $531 million, showing this data stack is already a core commercial engine.

• Cloud analytics powers test interpretation
• Algorithms support diagnostics and research
• Software platforms scale enterprise use

Tempus AI’s AI models and cloud stack turn large clinical and molecular data sets into diagnostics, research access, and trial matching. In Q1 2025, Tempus AI reported revenue of $255.7 million, showing how this stack scales into real commercial demand.

• Cloud tools support fast data processing.
• AI improves diagnosis and trial matching.
• Scales offerings across care and research.

Tempus AI, Inc. depends on a deep scientific and clinical talent base across genomics, pathology, data science, and software. These teams build and run its tests and enterprise services, and that expertise is a key intangible asset that helps translate large-scale clinical data into usable products.

• Core edge: expert knowledge, not hardware.
• Supports test development and services.
• Links biology, data, and software.

Tempus AI, Inc. gives researchers access to the Tempus dataset through Lens, while Insights licenses de-identified data for enterprise use. With 7M+ de-identified records, these tools cut the time and cost of real-world evidence work and make large-scale clinical research easier.

• Lens for researcher access
• Insights for enterprise licensing
• 7M+ de-identified records
• Lower RWE barriers

Tempus AI’s Hub streamlines ordering and test-result delivery in one desktop and mobile workflow, so clinicians can move faster inside existing care processes. In 2025, Tempus AI reported revenue growth above 50% year over year, and this kind of workflow layer helps support adoption by reducing handoffs and making the platform easier to use at the point of care.

• One hub for orders and results
• Works on desktop and mobile
• Fits clinical workflows better

Tempus AI’s clinical and scientific support helps customers interpret diagnostics and use data tools with confidence. In Q1 2025, Tempus AI reported $255.7 million in revenue, up 75.4% year over year, showing the scale behind that service and why practitioners and researchers trust it.

• Clinical help improves result use
• Scientific expertise builds trust
• Scale supports faster adoption

Tempus AI, Inc. builds recurring service ties through testing, data licensing, and trial services, so customers keep coming back as new patient data is generated. The model is reinforced by each new test and trial readout, which adds more data to use in future work.

• Repeat use across providers and biopharma
• Data grows with every new case
• Licensing and trials support ongoing revenue

Tempus AI, Inc. routes its diagnostics through physician ordering systems, then pushes results back into EHR and provider workflows, making clinical ordering and reporting a core go-to-market channel. In 2024, Tempus AI reported $531.0 million in revenue, and this workflow-led distribution helps convert test orders into repeat clinical use.

• Orders start in provider systems
• Results return to care teams
• Workflow access drives test adoption

Tempus AI, Inc.'s Trials matching workflow is a pharma service channel that links real-world patient data to active trial openings, turning data search into trial execution. It helps bridge research and operations by moving eligible patients into the right studies faster.

In 2024, Tempus reported $531.4 million in revenue, showing the scale behind this channel as part of its data-driven clinical network.

• Connects patient data to trial matches
• Serves pharma as a service channel
• Bridges research and execution

Biotechnology companies use Tempus AI’s analytics and cloud tools to speed drug discovery, trial design, and biomarker work. They also tap Tempus AI’s research data access, which matters because this segment is data-heavy and moves fast.

• Analytics for R&D decisions
• Cloud tools for scalable workflows
• Research data access for discovery

Scientific researchers and academic users use Tempus AI’s Lens and Insights tools to query large, de-identified multimodal datasets, including clinical, molecular, and imaging data. This segment supports discovery work and publication-driven studies, helping teams test hypotheses faster across real-world evidence from Tempus AI’s growing data network.

• Uses de-identified multimodal data
• Analyzes large research datasets
• Supports discovery and publication

Tempus AI said its data and analytics base underpins research use cases that scale across oncology and related fields.

Tempus AI’s diagnostics and de-identified data services need tight governance, and that means ongoing spend on quality, privacy, and regulatory controls. In 2024, the Company reported $693.4 million of revenue, so even small compliance gaps can hit licensing, trust, and scale fast.

These systems are not optional overhead; they protect product clearance and customer adoption. Tempus AI also reported $366.5 million of gross profit in 2024, showing why quality and regulatory controls must be built into the cost base, not added later.

• Governance supports diagnostics trust.
• Privacy controls protect de-identified data.
• Compliance costs recur every year.

Tempus AI, Inc. carries meaningful cost in enterprise sales to pharma and biotech, since each deal needs specialist reps, clinical scientists, and long sales cycles. Partnership management and provider support also add steady overhead, but they help protect recurring relationships and keep repeat business flowing.

• Specialized enterprise sales teams are expensive.
• Partner and provider support adds recurring cost.
• These costs help retain repeat customers.

Tempus AI, Inc. sells trial matching to drug makers through its Trials program, charging for access to matching tools and related services. This turns Tempus AI, Inc. data network into clinical development revenue; in 2025, that model sat alongside total revenue of about $693 million in 2024, showing how trial services scale with data reach.

• Paid access for pharma trial matching
• Links data assets to development spend
• High-value, service-led revenue stream

Tempus AI, Inc. uses Hub, Lens, Next, and Algos to turn software into revenue by supporting ordering, access, and interpretation workflows. This platform layer helps deepen monetization across testing and data services; Tempus AI, Inc. reported about $693 million in revenue in 2024, showing how software usage can reinforce multiple lines.

• Hub, Lens, Next, Algos drive workflow usage
• They support ordering and interpretation
• Platform use lifts cross-sell revenue